Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with progressive muscular wasting and paralysis due to loss of motor neurons in the primary motor cortex, brainstem and spinal cord. Alterations of transcriptional activity due to an unbalance of the activity of histone acetyl transferases (HAT) and histone deacetylases (HDACs) have been described in a variety of neurodegenerative conditions in vitro and in vivo. HDACs can be grouped into four different classes with distinct cellular localization and functions. HDAC inhibitors have recently been discovered as potential neuroprotective drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A major limitation, however, lies in the broad spectrum of action of currently available HDAC inhibitors causing a variety of toxic side effects.
Keywords: Amyotrophic lateral sclerosis, neurodegeneration, transcriptional regulation, histone deacetylases, HDAC inhibitors, sirtuins
CNS & Neurological Disorders - Drug Targets
Title: Histone Deacetylation and Motor Neuron Degeneration
Volume: 9 Issue: 3
Author(s): S. Schmalbach and S. Petri
Affiliation:
Keywords: Amyotrophic lateral sclerosis, neurodegeneration, transcriptional regulation, histone deacetylases, HDAC inhibitors, sirtuins
Abstract: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with progressive muscular wasting and paralysis due to loss of motor neurons in the primary motor cortex, brainstem and spinal cord. Alterations of transcriptional activity due to an unbalance of the activity of histone acetyl transferases (HAT) and histone deacetylases (HDACs) have been described in a variety of neurodegenerative conditions in vitro and in vivo. HDACs can be grouped into four different classes with distinct cellular localization and functions. HDAC inhibitors have recently been discovered as potential neuroprotective drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A major limitation, however, lies in the broad spectrum of action of currently available HDAC inhibitors causing a variety of toxic side effects.
Export Options
About this article
Cite this article as:
Schmalbach S. and Petri S., Histone Deacetylation and Motor Neuron Degeneration, CNS & Neurological Disorders - Drug Targets 2010; 9 (3) . https://dx.doi.org/10.2174/187152710791292684
DOI https://dx.doi.org/10.2174/187152710791292684 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Systematic Review of Drugs in Late-Stage Development for the Treatment of Multiple Sclerosis: A Focus on Oral Synthetic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: A Systematic Review
Current Gene Therapy Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases
Current Drug Targets Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry Applying Knowledge of Enzyme Biochemistry to the Prediction of Functional Sites for Aiding Drug Discovery
Current Topics in Medicinal Chemistry 2,5-Diketopiperazines as Neuroprotective Agents
Mini-Reviews in Medicinal Chemistry Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Gene Expression Studies in Multiple Sclerosis
Current Genomics Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Cholesterol, Alzheimers Disease, Prion Disorders: A menage a trois?
Current Drug Targets Activity-dependent Synaptic Plasticity and Metaplasticity in Spinal Motor Networks
Current Pharmaceutical Design Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Gels and Jellies as a Dosage Form for Dysphagia Patients: A Review
Current Drug Therapy Role of Curcumin in Regulation of TNF-α Mediated Brain Inflammatory Responses
Recent Patents on Inflammation & Allergy Drug Discovery